Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis
Linda M.C. Koene, Eva Niggl, Ilse Wallaard, Martina Proietti-Onori, Diana C. Rotaru, Ype Elgersma
Linda M.C. Koene, Eva Niggl, Ilse Wallaard, Martina Proietti-Onori, Diana C. Rotaru, Ype Elgersma
View: Text | PDF
Research Article Neuroscience

Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis

  • Text
  • PDF
Abstract

Tuberous sclerosis complex (TSC), caused by heterozygous mutations in TSC1 or TSC2, frequently results in intractable epilepsy. Here, we made use of an inducible Tsc1-knockout mouse model, allowing us to study electrophysiological and molecular changes of Tsc1-induced epileptogenesis over time. We recorded from pyramidal neurons in the hippocampus and somatosensory cortex (L2/L3) and combined this with an analysis of transcriptome changes during epileptogenesis. Deletion of Tsc1 resulted in hippocampus-specific changes in excitability and adaptation, which emerged before seizure onset and progressed over time. All phenotypes were rescued after early treatment with rapamycin, an mTOR inhibitor. Later in epileptogenesis, we observed a hippocampal increase of excitation-to-inhibition ratio. These cellular changes were accompanied by dramatic transcriptional changes, especially after seizure onset. Most of these changes were rescued upon rapamycin treatment. Of the genes encoding ion channels or belonging to the Gene Ontology term action potential, 27 were differentially expressed just before seizure onset, suggesting a potential driving role in epileptogenesis. Our data highlight the complex changes driving epileptogenesis in TSC, including the changed expression of multiple ion channels. Our study emphasizes inhibition of the TSC/mTOR signaling pathway as a promising therapeutic approach to target epilepsy in patients with TSC.

Authors

Linda M.C. Koene, Eva Niggl, Ilse Wallaard, Martina Proietti-Onori, Diana C. Rotaru, Ype Elgersma

×

Figure 1

Increased action potential firing throughout epileptogenesis.

Options: View larger image (or click on image) Download as PowerPoint
Increased action potential firing throughout epileptogenesis.
(A) Condit...
(A) Conditional, Cre-dependent, homozygous Tsc1 mouse model, color-coded for each experimental day (left) and timeline (right) of the experiments performed throughout epileptogenesis along with percentages of seizure onset on different days (based on previously published data; ref. 19). Squares on the timeline show the day of the patch-clamp measurements. (B) Representative examples of the whole-cell patch-clamp recordings from CA1 pyramidal neurons showing voltage responses to the current injection shown at the bottom. Scale bar indicates 100 ms and 40 mV. (C–F) Average number of action potentials of CA1 pyramidal neurons in response to increasing current injections of Tsc1-Cre– and Tsc1-Cre+ mice measured on day 4 (C), day 6 (D), day 8 (E), and day 12 (F) after gene deletion (day 4: Tsc1-Cre– n = 22, 4 mice; Tsc1-Cre+ n = 16, 3 mice; day 6: Tsc1-Cre– n = 16, 3 mice; Tsc1-Cre+ n = 16, 3 mice; day 8: Tsc1-Cre– n = 22, 5 mice; Tsc1-Cre+ n = 22, 5 mice; day 12: Tsc1-Cre– n = 21, 5 mice; Tsc1-Cre+ n = 21, 5 mice; 2-way RM ANOVA).*P < 0.05, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts